» Articles » PMID: 33549484

Euploidy Rates of Embryos in Young Patients with Good and Low Prognosis According to the POSEIDON Criteria

Overview
Publisher Elsevier
Date 2021 Feb 7
PMID 33549484
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Research Question: Does an association exist between ovarian reserve, ovarian response and embryonic euploidy in female patients under age 35 years?

Design: This was a retrospective analysis of intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidies cycles among patients enrolled at Bahceci Fulya IVF Center between January 2016 and August 2019. A total of 133 patients in POSEIDON group 1 (suboptimal responder; female age <35 years, antral follicle count [AFC] ≥5, number of oocytes retrieved <10) (group A), 133 patients in POSEIDON group 3 (expected low responder; female age <35 years, AFC <5) (group B) and 323 in the non-low-prognosis group (female age <35 years, AFC ≥5 and number of oocytes retrieved >9) (group C) were included.

Results: There was no significant difference in euploidy rate per embryo among the three groups (61.7% [145/235] for group A versus 53.5% [68/127] for group B versus 62% [625/1008] for group C; P = 0.13). The cancellation rate in cycles without a euploid blastocyst was significantly lower in group C than groups A and B (8.4% versus 12.8% and 16.5%; P = 0.034). Multivariate regression analysis indicated that the ovarian response group did not significantly affect the probability of obtaining a euploid embryo. Trophectoderm score 'C' (odds ratio 0.520, P = 0.007) and inner cell mass score 'C' (odds ratio 0.480, P < 0.001) were associated with a decreased probability of obtaining a euploid embryo.

Conclusions: These results confirm that POSEIDON group 1 and group 3 and non-low-prognosis patients have different probabilities of euploid embryos being obtained per cycle. However, euploidy rates per embryo are not affected by the patient's ovarian reserve and response.

Citing Articles

How to balance the live birth rate and the multiple pregnancy rate by selecting the cleavage-stage embryo number and quality for POSEIDON Group 1 and Group 2? A retrospective study.

He H, Liu R, Zhang Q, Geng L, Hou Z, Xu C Arch Gynecol Obstet. 2024; 311(2):507-517.

PMID: 39680145 PMC: 11890402. DOI: 10.1007/s00404-024-07850-2.


What is the optimal number of embryos to transfer for POSEIDON group 1 and group 2? A retrospective study.

Liu R, Zhang Q, Geng L, He H, Xu C, Feng J J Ovarian Res. 2024; 17(1):117.

PMID: 38822354 PMC: 11140960. DOI: 10.1186/s13048-024-01443-y.


Cumulative live birth rates and birth outcomes after IVF/ICSI treatment cycles in young POSEIDON patients: A real-world study.

Yan E, Li W, Jin H, Zhao M, Chen D, Hu X Front Endocrinol (Lausanne). 2023; 14:1107406.

PMID: 37065757 PMC: 10098357. DOI: 10.3389/fendo.2023.1107406.


A Mini-Review Regarding the Clinical Outcomes of In Vitro Fertilization (IVF) Following Pre-Implantation Genetic Testing (PGT)-Next Generation Sequencing (NGS) Approach.

Doroftei B, Ilie O, Anton N, Armeanu T, Ilea C Diagnostics (Basel). 2022; 12(8).

PMID: 36010262 PMC: 9406843. DOI: 10.3390/diagnostics12081911.


Blastocyst versus cleavage transfers: who benefits?.

Dirican E, Olgan S, Sakinci M, Caglar M Arch Gynecol Obstet. 2021; 305(3):749-756.

PMID: 34487220 DOI: 10.1007/s00404-021-06224-2.